Endogenous tripeptide thiol antioxidant and phase II conjugation cofactor
The principal low-molecular-weight thiol in mammalian cells, serving as the dominant intracellular antioxidant, electrophile conjugation substrate, and redox signaling mediator across virtually all aerobic tissues.
Abstract
Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine; GSH) is a ubiquitous tripeptide thiol present in virtually all mammalian cells at intracellular concentrations of 1 to 10 millimolar, constituting the single most abundant non-protein sulfhydryl compound in animal tissues and the central node of cellular redox homeostasis. First isolated by Sir Frederick Gowland Hopkins in 1921 from yeast, blood, and muscle tissue and subsequently characterized as a gamma-linked glutamyl-cysteinyl-glycine tripeptide by Hopkins and colleagues over the following decade, glutathione occupies a singular position in biochemistry: it is simultaneously the principal intracellular reductant maintaining the thiol-disulfide balance of cytosolic and mitochondrial protein pools; the obligate cofactor for glutathione peroxidases (GPx1 through GPx8), glutathione S-transferases (GST alpha, mu, pi, theta, sigma, kappa, omega, and zeta classes), and glutaredoxins; and the substrate for phase II xenobiotic conjugation reactions that render electrophilic metabolites water-soluble for biliary and renal excretion. The reduced form (GSH) predominates under physiological conditions, typically exceeding the oxidized disulfide form (GSSG) by a ratio of 100:1 in the cytosol, with the GSH/GSSG redox couple establishing the electrochemical set point against which cellular redox-sensitive signaling cascades operate, including nuclear factor erythroid 2-related factor 2 (Nrf2) activation, NF-kappaB modulation, and apoptosis signal-regulating kinase 1 (ASK1) regulation.
Biosynthesis proceeds through two sequential ATP-dependent enzymatic steps: gamma-glutamylcysteine ligase (GCL, formerly gamma-glutamylcysteine synthetase) catalyzes the rate-limiting condensation of L-glutamate and L-cysteine via an atypical gamma-carboxyl peptide bond, and glutathione synthetase (GSS) subsequently ligates glycine to the gamma-glutamylcysteine dipeptide. Both enzymes are transcriptionally regulated by the Nrf2-Keap1-ARE (antioxidant response element) pathway, establishing a feedback loop in which oxidative or electrophilic stress induces Nrf2 nuclear translocation, upregulates GCL and GSS expression, and thereby increases glutathione synthesis capacity. Cysteine availability is typically the rate-limiting substrate for biosynthesis, a constraint that underwrites the therapeutic rationale for N-acetylcysteine (NAC) as an indirect glutathione precursor strategy.
The pharmacokinetics of exogenous glutathione are dominated by poor oral bioavailability. The intact tripeptide is a substrate for gamma-glutamyltransferase (GGT) at the intestinal brush border and for intraluminal peptidases, resulting in extensive presystemic hydrolysis. Early pharmacokinetic studies in humans reported negligible increases in plasma or erythrocyte glutathione after single oral doses of reduced glutathione. These findings, together with subsequent work on liposomal, sublingual, and S-acetyl glutathione delivery systems that partially circumvent presystemic hydrolysis, have rekindled interest in direct glutathione supplementation as a complement to the established precursor strategy.
Clinically, glutathione depletion has been documented in a broad spectrum of disease states characterized by chronic oxidative stress, including Parkinson disease (40 percent depletion in the substantia nigra at preclinical stages), nonalcoholic fatty liver disease, chronic obstructive pulmonary disease, HIV/AIDS, cystic fibrosis, and age-related decline. Interventional evidence remains modest relative to the scope of the preclinical and epidemiological literature. In hepatic applications, intravenous glutathione is used clinically in several jurisdictions as adjunctive therapy for drug-induced liver injury and for the potentiation of NAC in acetaminophen toxicity, where the glutathione-NAPQI conjugation pathway is the principal detoxification mechanism.
This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.